CMS's New RAPID Coverage Pathway: What Genetic and Molecular Labs Should Know
Short answer: CMS wants Medicare coverage to start the same day the FDA approves certain breakthrough-designated devices — a category that can include genetic and molecular diagnostics. The formal "RAPID" coverage pathway notice published August 11, 2026, is still a proposal: CMS is taking public comments through October 10, 2026, and has paused its existing emerging-technology coverage track (TCET) while RAPID is finalized. No test has been covered through it yet.
What RAPID Actually Proposes to Do
CMS and FDA first floated a joint plan in April 2026 to shorten the gap between FDA market authorization and Medicare payment for breakthrough medical technology. That gap has long been a sore point for device and diagnostics makers: a product can clear FDA review and still wait months, sometimes years, before Medicare decides whether — and how much — to pay for it. In May 2026, the agencies proposed repealing the New Technology Add-on Payment "alternative pathway" and replacing it with the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. CMS published the formal procedural notice (CMS-3487-NC) in the Federal Register on August 11, 2026, opening a public comment period that runs through October 10, 2026.
As proposed, RAPID would let a device or diagnostic that holds FDA Breakthrough Device Designation — and clears FDA marketing authorization — receive a Medicare national coverage determination on an accelerated, potentially same-day basis, rather than starting a separate multi-month NCD review from zero after approval. It is a procedural alignment mechanism, not a guarantee: CMS retains its own "reasonable and necessary" evidence review, and the accelerated timeline applies only to products that request it and meet the program's criteria.
From TCET to RAPID: Why CMS Is Replacing Its Own Program
RAPID does not arrive in a vacuum. CMS has paused Transitional Coverage for Emerging Technologies (TCET) — the breakthrough-device coverage program it finalized in 2023 (CMS-3421-NC) — while RAPID is finalized, according to multiple health-policy trackers covering the August notice. TCET selected a limited number of breakthrough devices per year for an expedited coverage track with defined evidence-development requirements; RAPID is pitched as a broader, faster replacement. For labs and manufacturers that had been positioning a breakthrough-designated diagnostic for TCET, the practical message is that the on-ramp itself is changing mid-stream, and the successor pathway is not final.
Does RAPID Apply to Genetic and Molecular Diagnostics?
FDA's Breakthrough Device Designation program is open to devices broadly, and that legal definition of "device" already covers in vitro diagnostics — CMS itself has previously used a comparable simultaneous FDA-approval/Medicare-coverage mechanism for a molecular diagnostic: Foundation Medicine's FoundationOne CDx, a comprehensive genomic profiling test, received both FDA approval and a same-day proposed Medicare national coverage determination in November 2017 under the earlier Parallel Review Program. RAPID is a newer, broader mechanism built on that same basic idea — align FDA authorization and CMS coverage timing — rather than a program limited to implantable or surgical devices.
That history matters for labs developing or distributing breakthrough-designated genetic and molecular tests: if your test holds, or is pursuing, FDA Breakthrough Device Designation, RAPID (once finalized) is a pathway worth tracking alongside your regulatory strategy, not a program to assume applies only to cardiac or orthopedic devices.
The "Narrow Bridge": What RAPID Doesn't Fix
Coverage of the August notice has been cautious about overselling RAPID's near-term impact. One legal analysis published alongside the notice described it as "a narrow bridge over Medicare's coverage gap," and a health-policy newsletter tracking the rule argued the first genuinely same-day national coverage determination under RAPID will likely land well after 2030, given the procedural and evidentiary steps CMS says it will still require. RAPID is also, as of September 2026, only a proposal open for comment — not a final rule, and not yet available for any manufacturer or lab to use.
What Labs and RCM Teams Should Do Before October 10
Molecular and genetic testing labs with a breakthrough-designated product, or one in FDA's breakthrough device pipeline, have a concrete near-term action: read the CMS-3487-NC notice and consider submitting a comment before the October 10, 2026 deadline. Trade associations and law firms tracking the docket (Regulations.gov docket CMS-2026-2674) are already weighing in on eligibility criteria and evidence requirements — points that will shape whether a given diagnostic ultimately qualifies. RCM and market-access teams should treat RAPID the way they would any proposed rule affecting future coverage: as a planning input to flag for leadership and revisit once a final rule publishes, not as a program to build near-term revenue assumptions around. Labs currently navigating TCET should also confirm directly with CMS whether their product's TCET status is paused, grandfathered, or affected, since public trackers describe TCET as paused rather than terminated.
Educational Disclaimer
This article is provided for general educational and business-planning purposes for laboratory, revenue cycle, and clinical decision-support audiences. It is not legal, regulatory, coding, billing, or reimbursement advice for any specific device, test, or claim, and it does not constitute clinical guidance for patient care. RAPID is a proposed rule, not final policy — confirm current status directly with CMS, FDA.gov, and legal or regulatory counsel before making product-strategy or billing decisions.
FAQ
Is the RAPID coverage pathway final?
No. CMS published it as a procedural notice (CMS-3487-NC) in the Federal Register on August 11, 2026, and is accepting public comments through October 10, 2026. No device or diagnostic has been covered under RAPID yet.
What happened to TCET?
CMS has paused Transitional Coverage for Emerging Technologies, the breakthrough-device coverage program it finalized in 2023, while RAPID is developed as a potential successor. Trackers describe TCET as paused, not terminated — labs with products in that track should confirm status directly with CMS.
Does RAPID apply to genetic or molecular diagnostic tests, or only implantable devices?
The FDA Breakthrough Device Designation program, which RAPID builds on, applies to devices broadly, a category that includes in vitro diagnostics. CMS has used a comparable same-day approval-and-coverage mechanism for a molecular diagnostic before, under the earlier Parallel Review Program (FoundationOne CDx, 2017).
When could a lab actually use RAPID?
Not before CMS finalizes the rule following the comment period that closes October 10, 2026. At least one health-policy analysis tracking the notice projects the first true same-day national coverage determination under RAPID is unlikely before 2030, given the review steps CMS says it will retain.
Should labs comment on the proposal?
Labs with a breakthrough-designated diagnostic, or one pursuing that designation, have a direct stake in how CMS defines eligibility and evidence requirements. Comments are being accepted on Regulations.gov under docket CMS-2026-2674 through October 10, 2026.
Sources: Federal Register, CMS-3487-NC, Aug. 11, 2026; CMS.gov fact sheet, Regulatory Alignment for Predictable and Immediate Device Coverage Pathway; CMS and FDA joint press release, Apr. 2026; Ropes & Gray client alert, May 2026; Holland & Knight, "RAPID Coverage Pathway Comments Due October 10, 2026"; CMS press release, "FDA Announces Approval, CMS Proposes Coverage of First Breakthrough-Designated Test," Nov. 2017 (Parallel Review Program precedent). Related reading: Medicare Coverage for Genetic Testing: LCD, NCD & MolDX, Genetic Testing Insurance Denials, and the ScreenMyGene homepage.